Skip to main content
Premium Trial:

Request an Annual Quote

Genoma to Commercialize IntegraGen ASD Test

NEW YORK (GenomeWeb) – Molecular diagnostics firm IntegraGen today announced a distribution deal with Genoma to commercialize IntegraGen's Arisk autism spectrum disorder genetic risk assessment test outside the US. 

Financial and other terms of the deal were not disclosed. 

IntegraGen CEO Bernard Courtieu said in a statement that the test will allow physicians to refer and diagnose children with ASD and to start treatments when they are most effective, before the age of three. Genoma, an Italian molecular genetics laboratory, plans to offer the test to all geographies where it operates, the firms said. It will be used to test children with suspected developmental disorder and to test children with older siblings previously diagnosed with ASD. 

Genoma will also provide genetic consulting services to the parents, as well as all diagnostic services to the children and their parents, IntegraGen said. 

IntegraGen is based in Evry, France. Courtieu said that with children being diagnosed with autism when it is too late to implement early interventional treatment options, "the utilization of this test will contribute to earlier clinical diagnosis and improve the care of children with" ASD.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.